{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"88.8","upperLimit":"94.8","value":"91.76"},{"groupId":"OG001","lowerLimit":"85.0","upperLimit":"96.0","value":"90.53"},{"groupId":"OG002","lowerLimit":"82.2","upperLimit":"89.9","value":"86.06"},{"groupId":"OG003","lowerLimit":"78.0","upperLimit":"91.8","value":"84.89"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"372"},{"groupId":"OG001","value":"147"},{"groupId":"OG002","value":"367"},{"groupId":"OG003","value":"145"}],"units":"Participants"}],"description":"Disease-free survival defined as time from randomization end of induction to first event (relapse, second malignant neoplasm, remission death) or date of last contact for those who are event-free.","dispersionType":"95% Confidence Interval","groups":[{"description":"No Nelarabine, Capizzi Methotrexate","id":"OG000","title":"ARM I (Combination Chemotherapy)"},{"description":"Nelarabine, Capizzi Methotrexate","id":"OG001","title":"ARM II (Combination Chemotherapy)"},{"description":"No Nelarabine, High-Dose Methotrexate","id":"OG002","title":"ARM III (Combination Chemotherapy)"},{"description":"Nelarabine, High-Dose Methotrexate","id":"OG003","title":"ARM IV (Combination Chemotherapy)"}],"paramType":"NUMBER","populationDescription":"Includes only T-cell Acute Lymphoblastic Leukemia (T-ALL) patients randomized to Capizzi Methotrexate (CMTX) versus High-Dose Methotrexate (HDMTX). CNS3 patients non-randomly assigned to HDMTX (Arms III and IV) and Induction failures non-randomly assigned to Arm IV were excluded. T-LLY patients are excluded.","reportingStatus":"POSTED","timeFrame":"4 years from randomization at the end of induction","title":"Disease-free Survival (DFS) for Randomized Methotrexate T-ALL Cohort (Arm I vs. Arm II vs. Arm III vs. Arm IV)","type":"PRIMARY","unitOfMeasure":"percent probability"}